Oral Terbinafine Treatment for Ringworm

Introduction to Treatment Guidelines

• The American College of Dermatology recommends oral terbinafine 250 mg once daily for 2-4 weeks for cutaneous ringworm (tinea corporis/cruris) when systemic therapy is indicated 1

Treatment Indications and Duration

• Oral therapy is indicated for extensive infections, those involving hair follicles, or infections not responding to topical treatment within 2 weeks 2
• For tinea capitis (scalp ringworm), topical therapy alone is not recommended and oral therapy is generally indicated 2

Standard Dosing for Cutaneous Ringworm

• Adults should receive 250 mg once daily for 2-4 weeks 1
• Children <20 kg should receive 62.5 mg once daily for 2-4 weeks 1
• Children 20-40 kg should receive 125 mg once daily for 2-4 weeks 1
• Children >40 kg should receive 250 mg once daily for 2-4 weeks 1

Clinical Efficacy and Safety

• Short treatment duration (2-4 weeks) improves patient compliance compared to longer regimens 1
• The endpoint of treatment should be mycological rather than just clinical cure 1
• Treatment failure may be due to poor compliance, suboptimal drug absorption, or organism insensitivity 1

Safety Monitoring and Contraindications

• Baseline monitoring is particularly important in patients with history of heavy alcohol consumption, hepatitis, or haematological abnormalities 3
• Complete full blood count is recommended in patients with pre-existing risk factors 3
• Active or chronic liver disease is an absolute contraindication for oral terbinafine 3
• Lupus erythematosus and porphyria are also absolute contraindications for oral terbinafine 1

Common Side Effects and Serious Adverse Events

• Gastrointestinal disturbances (49%): nausea, diarrhea, dyspepsia, abdominal pain 3
• Dermatological reactions (23%): rash, pruritus, urticaria 3
• Incidence of serious adverse events is approximately 0.04% 3

Drug Interactions and Special Populations

• Terbinafine has minimal drug-drug interactions compared to azole antifungals 3
• The only potentially significant interaction is with drugs metabolized by cytochrome P450 2D6 isoenzyme 3
• Contraindicated in pregnancy 4
• Manufacturers caution against men fathering a child for 6 months after therapy 4

Evidence‑Based Safety Profile and Alternatives for Oral Terbinafine

Adverse Effects

• Permanent taste disturbance occurs in approximately 1 in 400 patients receiving oral terbinafine, indicating a rare but potentially irreversible sensory side‑effect. 5

Drug‑Interaction Considerations

• Co‑administration of rifampicin markedly lowers terbinafine plasma concentrations, while cimetidine significantly raises them, necessitating dose or monitoring adjustments when these agents are used together. 5

Reproductive Precautions

• Manufacturers advise that men should avoid attempting conception for at least 6 months after completing terbinafine therapy, reflecting concerns about possible drug‑related effects on sperm quality. 6

Alternative Oral Antifungal Therapy

• In patients who cannot receive terbinafine, oral itraconazole 100–200 mg once daily for 15 days achieves an 87 % mycological cure rate in adolescents and adults with tinea corporis, though liver‑function monitoring is required for treatment courses exceeding one month. 5